Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program

BACKGROUND: An intranasal formulation of esketamine, combined with an oral antidepressant, is approved in the USA and the European Union for adults with treatment-resistant depression (TRD). Transient cardiovascular stimulatory effects have been reported with ketamine. METHODS: Cardiovascular effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Doherty, Teodora, Wajs, Ewa, Melkote, Rama, Miller, Janice, Singh, Jaskaran B., Weber, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048867/
https://www.ncbi.nlm.nih.gov/pubmed/31994024
http://dx.doi.org/10.1007/s40263-020-00699-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048867/
https://www.ncbi.nlm.nih.gov/pubmed/31994024
http://dx.doi.org/10.1007/s40263-020-00699-4

Ejemplares similares